Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...

Alvotech (ALVO), a commercial-stage global biotech company specializing in the development and manufacture of biosimilar medicines, ...

In its Q3 2024 investor letter, Polaris Global Equity Strategy discussed the strong performance of the US biopharma sector, ...

To select stocks with long-term growth potential, investors should focus on fundamental analysis, evaluating financial health ...

This week, the department of pharmaceuticals (DoP) said the Indian arm of US firm AbbVie violated the newly amended Uniform Code for Pharmaceutical Marketing Practices. What did AbbVie do, and ...

Blue Cross Blue Shield of Michigan announced plans in November to drop coverage for Humira, a popular but costly auto-immune drug, in favor of a lower-cost alternative. Credit: Bloomberg Rising costs ...

The company's immunology portfolio, particularly Skyrizi and Rinvoq, has been a key driver of growth, helping to offset the anticipated decline in Humira sales due to biosimilar competition.

AbbVie’s blockbuster Humira held 105 patents, shielding the anti-inflammatory drug from biosimilar competition for more than 20 years. Proposed reforms could help prevent companies from extending ...

Perhaps the most notable example is Humira, a blockbuster branded drug which faced competition from biosimilars. AbbVie reported FY 2023 global revenues for Humira at $14.5B, down 32.2% from its ...

The reference adalimumab (Humira) is available in its original lower-concentration formulation and a high-concentration, citrate-free formulation. Some adalimumab biosimilars use citrate as a buffer, ...